The Yale School of Medicine and CT Pharmaceuticals Solutions Inc. have teamed up to conduct a study on the impact of medical marijuana on stress and mental health.
On Friday, Yale and CT Pharmaceuticals announced that they would be conducting a phase-one study on the effects of a variety of cannabis strains with medicinal qualities for alleviating pain and stress. They will also examine other conditions such as PTSD (post-traumatic stress disorder), and opioid replacement.
This is a revolutionary clinical study which is the first of its kind to be approved by the state’s Department of Consumer Protection (DCP) medical marijuana research program to study stress and mental health, said Yale.
The study on stress and mental health will advance CT Pharma’s current research which involves human subjects. CT Pharma’s current research was started in 2016 by Yale’s Dr. Rajita Sinha.
In 2017, the Food and Drug Administration (FDA) gave Sinha in collaboration with the CT Pharma, a go-ahead for an Investigational New Drug application to examine how marijuana products affect subjective and physical responses to stress and pain.
In a news release, Sinha said that there is an increase in the consumption of medical marijuana in America, and it is crucial to understand how it helps in relieving a patient’s symptoms. She further said that the study should come up with new findings on pain and stress management in patients using medical marijuana. It should also contribute to the development of new CBD-based treatments.
The first phase of the study will examine males and females between the ages of 21-45. They must be recreational weed consumers who do not qualify for MMJ cards. The second phase will include men and women suffering from chronic pain between the ages of 21-60. Each of the study participants will be provided with placebo and cannabidiol (CBD). CBD is the non-psychoactive compound of marijuana, famous for its healing and wellness benefits.
The study will also assess marijuana’s side effects, such as increased heart rate, systolic, and diastolic blood pressure as well as other clinical symptoms.
The study on stress and mental health comes days after the Connecticut lawmakers added new conditions such as interstitial cystitis, intractable neuropathic pain, medial arcuate ligament syndrome, and Tourette syndrome to the medical marijuana program. The Connecticut MMJ program now has 36 qualifying conditions for adults and 10 for patients under 18 years.
According to CT Pharma, there are 37,927 patients in the MMJ program, 1,196 certified physicians, 15 licensed dispensaries, and four producers in Connecticut. The largest concentration of registered patients is in Hartford, Fairfield, and New Haven.
CT Pharma has 40 employees, and it is planning to expand by moving into a larger facility, which is 173,000 square-foot located in Rocky Hill. The facility was previously occupied by a pharmaceutical company known as McKesson Corp.
This kind of independent research is what marijuana industry players like Youngevity International Inc. (NASDAQ: YGYI) and Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) have always wanted to see so that the public can be reassured that when the industry says marijuana is beneficial, it is true.
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Do you have a questions or are you interested in working with CNW420? Ask our Editor
CNW420 is part of the InvestorBrandNetwork.